Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019
Novel Treatment Options for High-Risk/Eldery AML Patients: CPX-351, Glasdegib + LDAC & Venetoclax + Hypomethylating Agents
Login to view comments.
Click here to Login
Malignant Hematology